Antiarrhythmic Drugs in AF

Slides:

Advertisements

Similar presentations

Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients With Nonvalvular Atrial Fibrillation SPORTIF V Trial Presented at American.

Advertisements

Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Antiarrhythmic Drugs for Maintaining Sinus Rhythm.

Journal of the American College of Cardiology Vol. 61, No. 4, 2013 Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation.

Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Non-valvular Atrial Fibrillation.

Addressing the Challenges in Primary and Secondary Stroke Prevention

The European Society of Cardiology Presented by Dr. Bo Lagerqvist

Covering the Bases in Cardioversion

CHA2DS2-VASc Scoring System General AF Treatment Guidance.

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.

Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.

Updates in Anticoagulation: What Did We Learn From ESC 2017?

US Guidelines US Guidelines Low-risk Patients.

NOACs, AF, and PCI: What Do the Latest Data Suggest?

Thrombosis, Cancer, and NOACs

The ABCs of AF.

Access to NOAC Therapy:

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

Emergency Management of NOAC Bleeding

A New Era for NOACs:.

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Up to Date on Which NOAC for Which Patient

New Perspectives in AF and PCI: Implications for the Practicing Physician.

Through Thick and Thin.

Oral Anticoagulants in AFa,b A Brief History.

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS

How to Adjust Anticoagulant Dosing

Diabetes Increases Risk of CVD

Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:

Efficacy and Safety of Edoxaban in Patients With AF and HF

Access to NOAC Therapy:

TAVR and the Risk of Thrombosis

What Anticoagulant Registries Are Revealing

A Better Solution For Cancer Patients With VTE?

Oral Anticoagulation in AF

Probiotics in the Prevention of C Difficile Infection

Dos and Don’ts for High-Risk Elderly Patients With AF

Extending Treatment for Thrombosis: What’s the Right Choice?

Practical Considerations to Extend Treatment for VTE

Atrial Fibrillation.

Extraordinary Cases of VTE Prevention in Patients With Cancer

NOACs in AF: Consequences of Underdosing and NonAdherence

Aspirin and Cardioprevention in 2018

Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials

A Time for Change for Managing Patients With VTE Who Have Cancer

What You Didn't Know About AF and Renal Dysfunction

Cancer-Associated Thrombosis

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Updates in Anticoagulation: Key Sessions at ESC 2017

Managing Pulmonary Embolism Posthospital Discharge

NOACs in AF: Consequences of Underdosing and NonAdherence

Elevated Admission Plasma Glucose Following ACS

ACC 2003 Late Breaking Trials

The ABCs of AF.

5 Good Minutes on Atrial Fibrillation-related Stroke

Omega-3s vs Pure EPA in Clinical Practice

How to Adjust Anticoagulant Dosing

Real-World Data in Cardiology: Focus on Atrial Fibrillation

Extraordinary Cases in Stroke Prevention

The Power of As-Treated Analyses

Antithrombotic Therapy in AF Patients Undergoing PCI

What's New in NOACs in AF?.

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

Antiarrhythmic Drugs in AF

Introduction

Clinical Status and Concurrent Conditions Influence Selection of Class IA AADs

Selection According to Patient-Specific Considerations and AAD Safety Profile

Real-World Data From Germany 62 Cardiology Practices: 2010 to 2017

Interpreting Observational Study Data

Analysis of Concurrent Medications With NOAC for Nonvalvular AF: Major Bleeding Risk

Analysis of Patients With AF in Sweden Risk of Major Bleeding

Analysis of Patients With AF in Sweden Primary Endpoint

Analysis of >44,000 Patients With AF in Sweden Composite Endpoint

AADs for Maintaining Sinus Rhythm After Cardioversion of AF: Cochrane Analysis

Network Meta-Analysis Data From 40 Randomized Controlled Trials

Summary

Abbreviations